How to value a biotech
For many biotech businesses, value sits in the future potential of pipeline assets, clinical milestones, market opportunity, regulatory outcomes, competitive positioning and the probability of commercial success. For pre-revenue and early-stage biotech companies, valuation also depends on how an asset could create value through partnering, licensing, acquisition or future commercialization. Investors and strategy teams need […]
ADCs remain in dealmakers’ sights. Here’s why
Antibody-drug conjugates remain red-hot in 2026’s biopharma M&A splurge. The overall ADC category will be worth $57 billion by 2032, according to Evaluate Pharma. Gilead’s $3 billion acquisition of Tubulis and Lilly’s of CrossBridge Bio are two of the latest deals. More will come as ADCs expand to hit new targets and carry new payloads. […]
A Clearer View from JPM 2026 – Day Four
The final day of JPM 2026 didn’t bring any late-breaking megadeals or big surprise announcements but there was plenty to keep biotech watchers engaged to the end. Our Biomedtracker team has summarized all the presentations in their Day Four report which you can download here, and below are a few highlights to ponder. Large cap […]
A Clearer View from JPM 2026 – Day Three
Day Three of JPM 2026 continued with a sense of both positivity and stability – both noticeably lacking in recent years. Here are a few of the highlights from the Biomedtracker team and you can catch up with all the action from Day Three in our full report which is available here. Mega cap momentum […]
A Clearer View from JPM 2026 – Day Two
Day Two at JPM carried a similar message from Day One: focus where you can win, deploy capital with discipline, and back assets with real clinical traction. Our Biomedtracker team has captured every detail in the full report which is available here, but here are some highlights. Mega caps sharpen their growth engines AstraZeneca’s session […]
A Clearer View from JPM 2026 – Day One
Here we are again. January means the JP Morgan Healthcare Conference and all eyes in the pharma and biotech space turn to San Francisco. Our Biomedtracker team is providing daily reports to bring you the highlights of each day’s activities. There’s loads to digest in the full Day One report, so here are a few […]
How Biotechs Can Win Capital in 2026: Highlights from Evaluate’s Financing Forum
January may be upon us but allow me one chance to look back at one of December’s highlights; Evaluate’s event that took place in London. Evaluate Financing Forum: Biotech Strategies for Accessing Capital saw more than 50 professionals from pharma, biotech and financing come together for a morning of networking and knowledge sharing about biotech […]
Strategic Deals and Investment Moves Influencing the GLP-1 Marketplace
While the rapid growth of the GLP-1 and obesity market presents enormous financial opportunities for life sciences companies, it also carries legal, regulatory, and reimbursement risks. With that in mind, Norstella were recently invited to present a session at the American Conference Institute Inaugural Summit on GLP-1 Law & Policy, Using deals data from Evaluate […]
Back from BIO: The Evolving Biotech Investment Landscape
“Nuclear winter” and “extinction event” were two of the less-than-positive terms used during last month’s BIO International convention to describe the state of play for biotechs in recent years. Fortunately, while this may be only a partial exaggeration, there were many more positive notes as well. Fresh from my third BIO International and after digesting […]
Three Things we Learned in our World Preview 2025 Webinar
Every year, I am hugely fortunate to work with our team of experts to create the Evaluate World Preview report. Now in its 18th year, the World Preview offers a data-rich look at the future of the pharmaceutical industry. It’s full of forecast data that help to paint a picture of the shifting sands of […]
